Lava Therapeutics clinical trials
Acquired by Ligand Pharmaceuticals Incorporated, Jul 14, 2026 · source ↗
The registry lists 2 studies whose lead sponsor is Lava Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 1, 2025.
Before and after it joined Ligand Pharmaceuticals Incorporated
- First submitted before Lava Therapeutics became part of Ligand Pharmaceuticals Incorporated
- 2
- First submitted after Lava Therapeutics became part of Ligand Pharmaceuticals Incorporated
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Lava Therapeutics2 studies
Something wrong with this grouping? Tell us on the Ligand Pharmaceuticals Incorporated page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Ligand Pharmaceuticals Incorporated studies →
- Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate CancerTerminatedNCT05369000Phase 1
Sponsor listed in the registry: Lava Therapeutics · First submitted before Lava Therapeutics became part of Ligand Pharmaceuticals Incorporated
- Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AMLTerminatedNCT04887259Phase 1
Sponsor listed in the registry: Lava Therapeutics · First submitted before Lava Therapeutics became part of Ligand Pharmaceuticals Incorporated